Camber debuts two generics
Camber is introducing two new generics.
The company is offering dabigatran etexilate capsules, which are the generic of Pradaxa.
Dabigatran etexilate capsules are a direct thrombin inhibitor, indicated to reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation.
Camber’s generic Pradaxa is available in 75 and 150 mg strengths in 60 count bottles.
[Read more: Camber intros generic Trileptal]
Camber also is debuting lamotrigine ER tablets, which are the generic of Lamictal XR.
Lamotrigine ER tablets are indicated as adjunctive therapy for primary generalized tonic-clonic seizures and partial-onset seizures with or without secondary generalization in patients aged 13 years and older.
[Read more: Camber debuts generic Epaned]
Camber's generic Lamictal XR tablets are available in 25, 50, 100, 200, 250, and 300 mg strengths in 30 count bottles.